TITLE

DSM considers alliance

PUB. DATE
June 2007
SOURCE
ICIS Chemical Business;6/25/2007, Vol. 2 Issue 72, p60
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the proposed partnership of DSM Nederland B.V. with North China Pharmaceutical Corp. to produce and market anti-infectives in China. According to the company, the partnership will possibly put into a separate entity and partial divestments which they expect to take an impairment charges of around $147 million.
ACCESSION #
25636658

 

Related Articles

  • DSM and NCPC Sign Contracts to Establish Nutrition and Anti-infectives JV in Hebei. Shi, Lina // China Chemical Reporter;4/6/2009, Vol. 20 Issue 10, p10 

    The article reports that Royal DSM NV and North China Pharmaceutical Group Corp. Ltd. (NCPC Group) have signed contracts to establish joint ventures (JVs) in the areas of nutritional products and anti-infective agents in the province of Hebei, China. As part of these contracts, Royal DSM will...

  • DSM Intends to Participate in North China Pharmaceutical.  // China Chemical Reporter;12/6/2004, Vol. 15 Issue 34, p6 

    Reports on the agreement between Royal DSM NV and North China Pharmaceutical Group Corp. in Shijiazhuang, Hebie Sheng, China. Terms of the agreement; Participation of DSM in the equity ownership of North China Pharmaceutical Co. Ltd.; Benefits of the partnership for both firms; Significance...

  • DSM to Invest in Anti-Infectives in China. Ramesh, Deepti // Chemical Week;3/30/2009, Vol. 171 Issue 9, p23 

    The article reports on a contract signed by DSM with North China Pharmaceutical Group Corp. to establish three separate joint ventures for nutritional products and anti-infectives in China. An investment totaling $110 million would be made by DSM for the ventures. DSM has also expressed plans to...

  • Achillion, FOB Synthesis Partner in Antibiotic Deal of Up to $10M.  // BioWorld Today;4/9/2008, Vol. 19 Issue 69, p3 

    The article reports on the partnership between Achillion Pharmaceuticals Inc. and FOB Synthesis Inc. It relates the amount that FOB Synthesis will receive from Achillion for in-licensing its antibiotic compounds. Under the deal, Achillion acquired the worldwide rights for research, development...

  • Dow and SPI to make antimicrobial medical scrubs & lab coats.  // Man-Made Textiles in India;May2015, Vol. 43 Issue 5, p202 

    The article announces the partnership of Dow Microbial Control, a business unit of The Dow Chemical Co. and medical apparel and lab wear designer and manufacturer Strategic Partners Inc., (SPI) to develop the next generation of medical scrubs and lab coats. Topics covered include the Silvadur...

  • Innovation. Baker, John // ICIS Chemical Business;6/11/2007, Vol. 2 Issue 70, p30 

    The article reports on the decision of BASF and U.S.-based Agion Technologies to develop styrenic copolymers with antimicrobial protection, initially for the European market. The development will focus on applying the silver-based antimicrobial technology of Agion in BASF's Luran S...

  • North China Pharmaceutical: Changes Along with the New Medical Reform.  // China Chemical Reporter;4/26/2009, Vol. 20 Issue 12, p24 

    The article discusses how the changes of China's New Medical Reform affect the transactions of North China Pharmaceutical Co. Ltd. The company changes its focus on drug preparations instead of bulk drugs. Moreover, it cites that the company is moving its factories in the urban areas of...

  • North China Pharmaceutical to Raise R & D Ability.  // China Chemical Reporter;1/26/2009, Vol. 20 Issue 3, p8 

    The article reports on the announcement of North China Pharmaceutical Company Ltd. based in Shijiazhuang, Hebei province on January 9, 2009. The company intends to acquire a 77.84% interest in NCPC New Drug R&D Co., Ltd. from North China Pharmaceutical Group Corporation (NCPC), to strengthen its...

  • Going Dutch on vitamin deal. Robinson, Simon // European Chemical News;10/31/2005, Vol. 83 Issue 2169, p7 

    This article reports on the plan of Dutch specialty materials and life sciences group DSM to invest $164 million in its vitamins and antibiotics joint ventures with North China Pharmaceutical Group Corporation as part of an agreement revealed in November 2004. The Dutch chemicals and life...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics